戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ilar way to SGLT2is without a higher risk of diabetic ketoacidosis.
2         An SQ insulin treatment protocol for diabetic ketoacidosis.
3  monitoring, especially for the diagnosis of diabetic ketoacidosis.
4 as chronic obstructive pulmonary disease and diabetic ketoacidosis.
5 tive clinical stigma as they are involved in diabetic ketoacidosis.
6  with type 1 diabetes because of the risk of diabetic ketoacidosis.
7 thout coronavirus disease (COVID-19) who had diabetic ketoacidosis.
8 d should be avoided where there is a risk of diabetic ketoacidosis.
9 luding a roughly six-times increased risk of diabetic ketoacidosis.
10 boratory studies also showed the presence of diabetic ketoacidosis.
11  prolonged fasting or streptozotocin-induced diabetic ketoacidosis.
12 ly controlled diabetes, including a model of diabetic ketoacidosis.
13 a severe hypoglycemic event; no patients had diabetic ketoacidosis.
14                             Two children had diabetic ketoacidosis.
15  had an underlying cause of death of coma or diabetic ketoacidosis.
16 uding congestive heart failure, hypoxia, and diabetic ketoacidosis.
17 me in clinically ill pediatric patients with diabetic ketoacidosis.
18 pendence in adult patients with a history of diabetic ketoacidosis.
19  provide a background for the development of diabetic ketoacidosis.
20  receptors causes early postnatal death from diabetic ketoacidosis.
21 96]; p<0.0001), and were more likely to have diabetic ketoacidosis (11% [61/537] vs 0.3% [30/11 696];
22 psis (41.1%), cardiogenic shock (20.9%), and diabetic ketoacidosis (16%).
23 nt in CGM group and 4 in the BGM group), and diabetic ketoacidosis (3 participants with an event in t
24 4.42 [95% CI, -6.15 to -2.69]; P < .001) and diabetic ketoacidosis (3.64 vs 4.26 per 100 patient-year
25 s 1, respectively; P > .99) and 11 developed diabetic ketoacidosis (5 vs 3 vs 3, respectively; P = .7
26  the use of intensive care for patients with diabetic ketoacidosis, a common condition with a low ris
27  cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study.
28  During his hospitalization for treatment of diabetic ketoacidosis, acute renal failure, and sepsis,
29  adjustment, hospitals with a high volume of diabetic ketoacidosis admissions admitted diabetic ketoa
30 , with no episodes of severe hypoglycemia or diabetic ketoacidosis after randomization.
31          Wild type (WT) mice developed fatal diabetic ketoacidosis after streptozotocin, whereas GcgR
32 e IA-2 autoantibody, lower C-peptide, and no diabetic ketoacidosis (all, p < 0.05).
33 ol (blood glucose <120 mg/dL), prevention of diabetic ketoacidosis and absence of cataract developmen
34                                 A history of diabetic ketoacidosis and chronic hyperglycaemia appear
35 ontrolled diabetes with numerous episodes of diabetic ketoacidosis and frequent hypoglycemic episodes
36  prevalence of hypoglycemia in patients with diabetic ketoacidosis and hyperosmolar hyperglycemic sta
37       Moderate-intensity insulin therapy for diabetic ketoacidosis and hyperosmolar hyperglycemic sta
38 monly used in the hospital setting to manage diabetic ketoacidosis and hyperosmolar hyperglycemic sta
39 tations and an increase in diagnoses such as diabetic ketoacidosis and mental health issues.
40     Secondary outcomes were the frequency of diabetic ketoacidosis and parental psychological stress,
41 e participant in the CGM plus MDI group, and diabetic ketoacidosis and severe hyperglycaemia occurred
42                                              Diabetic ketoacidosis and severe hypoglycemia are acute
43  with lower risks of severe hypoglycemia and diabetic ketoacidosis and with better glycemic control d
44  metabolic status of pediatric patients with diabetic ketoacidosis and, along with pulse oximetry, in
45 tween glycaemic control (HbA1c), episodes of diabetic ketoacidosis, and all hospital admissions for a
46 anding, enabling earlier diagnosis, reducing diabetic ketoacidosis, and allowing timely introduction
47 ght to contribute to poor glycaemic control, diabetic ketoacidosis, and brittle diabetes in adolescen
48 nder certain conditions, such as starvation, diabetic ketoacidosis, and ketogenic diets, play a poten
49 or 4 adverse events reported were diarrhoea, diabetic ketoacidosis, and pneumonitis (one patient each
50 inase-3 might mediate vasogenic edema during diabetic ketoacidosis, and selective proteinase-3 antago
51 ine whether rates of severe hypoglycemia and diabetic ketoacidosis are lower with insulin pump therap
52 icipants included hospitalized patients with diabetic ketoacidosis at 21 hospitals between January 1,
53       This cohort study assesses the risk of diabetic ketoacidosis at the diagnosis of type 1 diabete
54       Two additional groups of children with diabetic ketoacidosis but without cerebral edema were al
55                                     Standard diabetic ketoacidosis care in the US includes intravenou
56 ry protocol for treating adult patients with diabetic ketoacidosis decreases intensive care and hospi
57 roportion of diabetes admissions were due to diabetic ketoacidosis (DKA) (90%) compared to the pre-wa
58  to placebo, while an increased incidence of diabetic ketoacidosis (DKA) (n = 16) was seen in SGLT-2
59  but life-threatening complication of severe diabetic ketoacidosis (DKA) and its treatment.
60 onal antibody, anti-CotH C2, which protected diabetic ketoacidosis (DKA) and neutropenic mice from mu
61 isks is not known in hyperglycemic crises of diabetic ketoacidosis (DKA) and nonketotic hyperglycemia
62                                Patients with diabetic ketoacidosis (DKA) are uniquely predisposed to
63                              Presenting with diabetic ketoacidosis (DKA) at onset of type 1 diabetes
64 ended dose (0.1 U/kg per hour) of insulin in diabetic ketoacidosis (DKA) guidelines is not backed by
65 requency of AKI in children hospitalized for diabetic ketoacidosis (DKA) has not been previously exam
66                                  Most often, diabetic ketoacidosis (DKA) in adults results from insuf
67 d-type mice, despite a significant degree of diabetic ketoacidosis (DKA) in all 14 animals.
68 es registry data to compare the frequency of diabetic ketoacidosis (DKA) in children and adolescents
69 requency of acute kidney injury (AKI) during diabetic ketoacidosis (DKA) in children, raising the que
70  edema is a life-threatening complication of diabetic ketoacidosis (DKA) in children.
71 potentially life-threatening complication of diabetic ketoacidosis (DKA) in children.
72                                              Diabetic ketoacidosis (DKA) is the most common acute com
73                                              Diabetic ketoacidosis (DKA) is the most common acute hyp
74       The mechanism by which leptin reverses diabetic ketoacidosis (DKA) is unknown.
75                                              Diabetic ketoacidosis (DKA) may cause brain injuries in
76 w that FTR1 is expressed during infection in diabetic ketoacidosis (DKA) mice.
77 esized that oxidative stress associated with diabetic ketoacidosis (DKA) of T1DM might have measurabl
78 ing complications of severe hypoglycemia and diabetic ketoacidosis (DKA) or hyperglycemic hyperosmola
79 otal insulin-days), glucose variability, and diabetic ketoacidosis (DKA) recurrences were compared fo
80 g or placebo alongside ketone monitoring and diabetic ketoacidosis (DKA) risk mitigation education.
81                          The co-existence of diabetic ketoacidosis (DKA) with acute pancreatitis (AP)
82 nfusion is the standard of care for treating diabetic ketoacidosis (DKA) worldwide.
83                                              Diabetic ketoacidosis (DKA), a severe complication of di
84 lemia, fractures, falls, genital infections, diabetic ketoacidosis (DKA), acute kidney injury (AKI),
85 d available serum iron, including those with diabetic ketoacidosis (DKA), are uniquely susceptible to
86 ncluding adjudicated severe hypoglycemia and diabetic ketoacidosis (DKA), stratified by CKD.
87                                              Diabetic ketoacidosis (DKA)-induced hypertriglyceridemia
88 ord terms related to COVID-19, diabetes, and diabetic ketoacidosis (DKA).
89 LT-2) inhibitors could increase the risk for diabetic ketoacidosis (DKA).
90 hat have been linked to an increased risk of diabetic ketoacidosis (DKA).
91 er COVID-19 increased HbA1c, risk of T2D, or diabetic ketoacidosis (DKA).
92 ich may underlie their proclivity to develop diabetic ketoacidosis (DKA).
93 hat developed during the treatment of severe diabetic ketoacidosis (DKA).
94                    Hyperglycemic crises (ie, diabetic ketoacidosis [DKA] and hyperglycemic hyperosmol
95 tcomes were rates of severe hypoglycemia and diabetic ketoacidosis during the most recent treatment y
96 , gastritis, pancreatitis and arthritis, and diabetic ketoacidosis each occurring in one (2%) patient
97          One severe hypoglycemia event and 1 diabetic ketoacidosis event occurred in each group.
98 f DKA, however, there were a small number of diabetic ketoacidosis events.
99 cipants experiencing severe hypoglycemia and diabetic ketoacidosis events.
100 ecognition of the clinical manifestations of diabetic ketoacidosis, followed by appropriate, timely t
101         The numbers of amputations, cases of diabetic ketoacidosis, fractures, and major hypoglycemic
102 rican-American persons with new diagnoses of diabetic ketoacidosis have clinical, metabolic, and immu
103 pe 1 diabetes with complications: ICC, 0.36; diabetic ketoacidosis: ICC, 0.33; acute appendicitis wit
104                                              Diabetic ketoacidosis in children is associated with vas
105                                        Acute diabetic ketoacidosis in children was associated with el
106  an uncommon but devastating complication of diabetic ketoacidosis in children.
107  5 in the standard-care group; 1 instance of diabetic ketoacidosis in each group; and 12 device-relat
108 e were no episodes of severe hypoglycemia or diabetic ketoacidosis in either group.
109  co-transporter-2 inhibitors and the risk of diabetic ketoacidosis in patients with type 2 diabetes:
110                           The development of diabetic ketoacidosis in pregnancy is a medical emergenc
111 utes to long-term poor glycaemic control and diabetic ketoacidosis in this age group.
112                Treatment of the patient with diabetic ketoacidosis includes insulin therapy and caref
113               Cerebral edema associated with diabetic ketoacidosis is an uncommon but severe complica
114                    Our results indicate that diabetic ketoacidosis is associated with systemic polymo
115 sthma, atrial septal defects, bronchiolitis, diabetic ketoacidosis, Kawasaki syndrome, mental health
116 hat the pathophysiology of cerebral edema in diabetic ketoacidosis may involve a transient loss of ce
117              Reported complications included diabetic ketoacidosis (n = 8), sepsis or septic shock (n
118 atients who are immunocompromised because of diabetic ketoacidosis, neutropenia, organ transplantatio
119                               No episodes of diabetic ketoacidosis occurred in either group.
120                    No severe hypoglycemia or diabetic ketoacidosis occurred in either group.
121                         Adjudicated definite diabetic ketoacidosis occurred in four (1%) patients in
122 e occurred in the control group; one case of diabetic ketoacidosis occurred in the closed-loop group.
123                                  One case of diabetic ketoacidosis occurred in the closed-loop group.
124 nts occurred in either group; one episode of diabetic ketoacidosis occurred in the closed-loop group.
125         A total of 7989 hospitalizations for diabetic ketoacidosis occurred, with 4739 (59.3%) occurr
126    Pediatric type 1 diabetes patients; acute diabetic ketoacidosis or age-/sex-matched insulin-contro
127                    There were no episodes of diabetic ketoacidosis or hyperglycemia with ketosis.
128 1 episode of severe hypoglycemia and none of diabetic ketoacidosis or hyperosmolar hyperglycemic synd
129                                Patients with diabetic ketoacidosis or hyperosmolar nonketotic coma we
130 nds at a median age of 9 weeks, usually with diabetic ketoacidosis or marked hyperglycemia, was not a
131                               No episodes of diabetic ketoacidosis or severe hypoglycemia occurred in
132  reversible metabolic causes of coma such as diabetic ketoacidosis or uremia were excluded.
133 10% glucose solution; a history of diabetes, diabetic ketoacidosis, or diabetes insipidus; a need for
134  adverse events, including volume depletion, diabetic ketoacidosis, or renal events, were similar wit
135 inversely related to hospital admissions for diabetic ketoacidosis (p < 0.001) and all hospital admis
136 s hospitals in the use of intensive care for diabetic ketoacidosis patients that was not associated w
137 of diabetic ketoacidosis admissions admitted diabetic ketoacidosis patients to the intensive care uni
138 ondiabetic ketoacidosis in-patients admitted diabetic ketoacidosis patients to the intensive care uni
139                    Use of intensive care for diabetic ketoacidosis patients varied widely across hosp
140  Plasma azurophilic enzymes were elevated in diabetic ketoacidosis patients, including human leukocyt
141           PetCO2 monitoring of patients with diabetic ketoacidosis provides an accurate estimate of P
142  eventually presented with hyperglycemia and diabetic ketoacidosis requiring insulin initiation.
143 ed, only proteinase-3 levels correlated with diabetic ketoacidosis severity (p = 0.002).
144  examined, only proteinase-3 correlated with diabetic ketoacidosis severity and potently degraded the
145 relate plasma azurophilic enzyme levels with diabetic ketoacidosis severity, and to determine whether
146 tCO2 sampling may be useful in patients with diabetic ketoacidosis to allow for continuous monitoring
147 a azurophilic enzyme levels in children with diabetic ketoacidosis, to correlate plasma azurophilic e
148 gest that a protocol based on SQ insulin for diabetic ketoacidosis treatment was associated with sign
149 n intern (anno 1953) treating a youngster in diabetic ketoacidosis underscored our ignorance of the c
150 e beta-hydroxybutyrate (BHB)-a biomarker for diabetic ketoacidosis-using a commercial combination BHB
151 human leukocyte elastase and proteinase-3 in diabetic ketoacidosis was confirmed with buffy coat quan
152                         However, the rate of diabetic ketoacidosis was higher in the sotagliflozin gr
153                                  The rate of diabetic ketoacidosis was higher in the sotagliflozin gr
154 wer than 7.0% with no severe hypoglycemia or diabetic ketoacidosis was larger in the group that recei
155 mine whether cerebral edema in patients with diabetic ketoacidosis was related to changes in cerebral
156                      Severe hypoglycemia and diabetic ketoacidosis were absent in patients with funct
157                                Patients with diabetic ketoacidosis were monitored with an oral/nasal
158 al mycotic infections, volume depletion, and diabetic ketoacidosis were more common with sotagliflozi
159 erious adverse device effects or episodes of diabetic ketoacidosis were reported.
160 ed to diabetes (two severe hypoglycemia, one diabetic ketoacidosis) were reported in the physician ar
161 tment-limiting and life-threatening, such as diabetic ketoacidosis, which appears to be more frequent
162                                Children with diabetic ketoacidosis who have low partial pressures of
163 ematemesis, abdominal distention, and severe diabetic ketoacidosis with hypotension.
164 ed 61 children who had been hospitalized for diabetic ketoacidosis within a 15-year period and in who

 
Page Top